Drug
D0478 | danazol
G
G03XA01 Danazol
[G03XA] Antigonadotropins and similar agents
[G03X] OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
[G03] SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
[G] Genitourinary system and reproductive hormones
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| ELECTRON TRANSPORT CHAIN | rat | isolated liver mitochondria | measurements of mitochondrial respiration; RST inhibition assay, RST uncoupling assay; IC 50ratio of glucose/galactose assay | decrease | 53 | |||
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Danger |
Aggregated GHS information provided by 60 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H312 (95%): Harmful in contact with skin [Warning Acute toxicity, dermal] H332 (95%): Harmful if inhaled [Warning Acute toxicity, inhalation] H351 (26.67%): Suspected of causing cancer [Warning Carcinogenicity] H360 (31.67%): May damage fertility or the unborn child [Danger Reproductive toxicity] H361 (68.33%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P261, P271, P280, P281, P302+P352, P304+P312, P304+P340, P308+P313, P312, P322, P363, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| rat | LD50 | intraperitoneal | > 10gm/kg (10000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 25, Pg. 691, 1983. | |
| man | TDLo | oral | 274mg/kg/32D- (274mg/kg) | Postgraduate Medical Journal. Vol. 69, Pg. 237, 1993. | |
| dog | LD50 | oral | > 5gm/kg (5000mg/kg) | Journal of International Medical Research. Vol. 5(Suppl, | |
| rabbit | LD50 | oral | > 5gm/kg (5000mg/kg) | Journal of International Medical Research. Vol. 5(Suppl, | |
| mouse | LD50 | intraperitoneal | 6770mg/kg (6770mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 14, Pg. 484, 1983. | |
| rat | LD50 | oral | > 17gm/kg (17000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 25, Pg. 691, 1983. | |
| women | TDLo | oral | 974mg/kg/23W- (974mg/kg) | Therapie. Vol. 43, Pg. 501, 1988. | |
| man | TDLo | oral | 1029mg/kg/17W (1029mg/kg) | liver: "jaundice, cholestatic" | Postgraduate Medical Journal. Vol. 68, Pg. 984, 1992. |
| women | TDLo | oral | 120mg/kg/10D- (120mg/kg) | skin and appendages (skin): "dermatitis, allergic: after systemic exposure" | Archives of Internal Medicine. Vol. 145, Pg. 2251, 1985. |
| rat | LD50 | subcutaneous | > 10gm/kg (10000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 25, Pg. 691, 1983. | |
| mouse | LD50 | subcutaneous | > 10gm/kg (10000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 25, Pg. 691, 1983. | |
| mouse | LD50 | oral | 4830mg/kg (4830mg/kg) | Zhongguo Yaoxue Zazhi. Chinese Pharmacuetical Journal. Vol. 25, Pg. 55, 1990. | |
| (17a)-Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol | (1R,3aS,3bR,10aR,10bS,12aS)-1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d][1,2]oxazol-1-ol | (1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol |
| (1S,2R,13R,14S,17R,18S)-17-ethynyl-2,18-dimethyl-7-oxa-6-azapentacyclo[11.7.0.0^{2,10}.0^{4,8}.0^{14,18}]icosa-4(8),5,9-trien-17-ol | 1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol | 1-ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-1H-Cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol |
| 17 alpha-pregna-2,4-dien-20-yno[2,3-D] isoxazol-17 beta-ol | 17-alpha-2,4-Pregnadien-20-yno(2,3-d)isoxazol-17-ol | 17-alpha-Pregn-4-en-20-yno(2,3-d)isoxazol-17-ol |
| 17-alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol | 17.Alpha.-Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol} | 17230-88-5 |
| 17a-Pregna-2,4-dien-20-yne-[2,3-d]isoxazole-17b-ol | 17a-Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol | 17alpha-Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol |
| 199957-EP2272825A2 | 199957-EP2275420A1 | 1H-Cyclopenta[7,8]phenanthro[3,2-d]isoxazole- pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol deriv.; |
| 2,3-Isoxazolethisterone | 2,4,17alpha-Pregnadien-20-yno[2,3-d]-isoxa-zol-17-ol | 230D885 |
| AC-6836 | AKOS015961192 | API0002209 |
| AS-13035 | BCP11914 | BDBM50423541 |
| BPBio1_000100 | BRD-K48970916-001-03-0 | BSPBio_000090 |
| Bonzol | C06938 | CAS-17230-88-5 |
| CCG-220105 | CCRIS 6747 | CHEBI:4315 |
| CHEMBL1479 | CS-4547 | Chronogyn |
| Cyclomen | D00289 | DB01406 |
| DSSTox_CID_2880 | DSSTox_GSID_22880 | DSSTox_RID_76772 |
| DTXSID2022880 | Danatrol | Danazol (JP17/USP/INN) |
| Danazol [USAN:BAN:INN:JAN] | Danazol [USAN:USP:INN:BAN:JAN] | Danazol, USP |
| Danazole | Danazolum | Danazolum [INN-Latin] |
| Danocrine | Danocrine (TN) | Danogen |
| Danokrin | Danol | Danoval |
| Danovaol | Danzol | EINECS 241-270-1 |
| GTPL6942 | HMS1568E12 | HMS2090A22 |
| HMS2095E12 | HMS2231M08 | HMS3259M10 |
| HMS3712E12 | HY-B1029 | LS-118524 |
| Ladogal | MCULE-5533294331 | MLS001066617 |
| MLS001306473 | N29QWW3BUO | NC00557 |
| NCGC00164400-01 | NCGC00179665-01 | NCGC00179665-02 |
| NCGC00179665-04 | NCGC00255335-01 | NSC 270916 |
| NSC-270916 | NSC270916 | Optina |
| Panacrine | Pregna-2, {4-dien-20-yno[2,3-d]isoxazol-17-ol,} (17.alpha.)- | Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol, (17alpha)- |
| Pregna-2,4-dien-20-yno(2,3-d)isoxazol-17-ol,(17alpha)- | Prestwick0_000105 | Prestwick1_000105 |
| Prestwick2_000105 | Prestwick3_000105 | Prestwick_150 |
| Q419652 | SCHEMBL21107 | SMR000058321 |
| SPBio_002029 | SR-01000760722 | SR-01000760722-2 |
| SR-05000000445 | SR-05000000445-2 | Tox21_112114 |
| Tox21_112114_1 | Tox21_301940 | UNII-N29QWW3BUO |
| Vasaloc | W-107864 | WIN 17,757 |
| WIN 17757 | WIN-17757 | Win 17, 757 |
| Win-17,757 | Winobanin | ZINC3881958 |
| [1,2]oxazolo[4',5':2,3]-17alpha-pregn-4-en-20-yn-17-ol | anatrol | danazol |
| ethynyl(dimethyl)[?]ol | s9506 |